Nelson Dusetti: Promising therapeutic strategies for targeting mitochondrial metabolism in pancreatic cancer cells

Nelson Dusetti shared a post on LinkedIn:

“Exciting new research from Pierre Cordelier’s team, which we had the privilege of contributing to, reveals that Cytidine Deaminase (CDA) does more than metabolize nucleotides.

It boosts mitochondrial function and could make cancer cells more vulnerable to targeted treatments. These findings underscore the intricate nature of metabolic reprogramming in this tumor type and point to promising therapeutic strategies for targeting mitochondrial metabolism in patients with elevated CDA expression. ”

Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells

Authors: Audrey Frances, Audrey Lumeau. Nicolas Bery, , Marion Gayral, Lucille Stuani, Marie Sorbara, Estelle Saland, Delphine Pagan, Naïma Hanoun, Jérôme Torrisani, Anthony Lemarié, Jean-Charles Portais, Louis Buscail, Nelson Dusetti, Jean-Emmanuel Sarry, Pierre Cordelier

Source: Nelson Dusetti/LinkedIn

Nelson Dusetii is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.